Dr. Mghazli M.A
🍷

Troubles liés à la consommation d'alcool

Séminaire The Lancet — Rehm, Assanangkornchai, Hendershot et al. — 9 octobre 2025

Psychiatrie & Addictologie
⚠️ Site destiné aux professionnels de santé — Contenu éducatif

🍷 Les troubles liés à l'usage d'alcool

Les troubles liés à la consommation d'alcool regroupent des affections caractérisées par une consommation excessive et compulsive et une perte de contrôle. Ils figurent parmi les troubles mentaux les plus répandus au monde.

~400M
Personnes avec
troubles alcooliques
3M
Dèces/an liés
à l'alcool
20%
Patients traités
(accès insuffisant)
+15%
Hausse mortalité
liée au COVID-19

📊 Prévalence des troubles liés à l'alcool par région du monde

💰 Coûts sociaux de l'alcool par catégorie

🏥 Affections attribuables à l'alcool

📈 Évolution de la consommation d'alcool par habitant (2010-2025)

📖
Article principal — The Lancet
Rehm, Assanangkornchai, Hendershot et al. — 9 octobre 2025
▼
📖 Résumé de l'article :
Aspect Contenu
Titre Alcohol use disorders
Type Séminaire (Review)
Journal The Lancet, Volume 406, Numéro 10516, p2269-2281
Date 9 octobre 2025
DOI 10.1016/S0140-6736(25)01496-5
🔑 Points clés de l'article :
  • Les troubles liés à l'usage d'alcool sont caractérisés par une consommation excessive et compulsive et une perte de contrôle
  • Ces troubles sont parmi les troubles mentaux les plus répandus au monde
  • La prévalence est plus élevée dans les pays à revenu élevé et plus faible dans les pays à faible revenu
  • La pandémie de COVID-19 a augmenté la mortalité entièrement attribuable à l'alcool
  • Les troubles restent insuffisamment traités malgré des interventions validées scientifiquement
  • Les deux obstacles principaux : faible disponibilité (absence de financement) et stigmatisation
🔗 Liens de l'article :
👥 Auteurs de l'article :
  • Pr. Jürgen Rehm — PhD (auteur principal)
    Email: jtrehm@gmail.com
  • Pr. Sawitri Assanangkornchai — MD
  • Pr. Christian S Hendershot — PhD
  • Ari Franklin — MPH
  • Maria Neufeld — MSc
  • Ahmed S Hassan — MSc
  • et al.
📋
Définition et diagnostic
DSM-5 et CIM-11 : critères diagnostiques
▼
📋 Définition selon l'article :

Les troubles liés à l'usage d'alcool regroupent des affections caractérisées par une consommation excessive et compulsive d'alcool et une perte de contrôle sur cette consommation.

🔬 Critères DSM-5 pour le trouble lié à l'usage d'alcool :
Critère Description
1. Consommation importante Plus que prévu, ou pendant plus longtemps que prévu
2. Désir persistant Envie forte ou tentative infructueuse de réduire
3. Temps considérable Much time spent to obtain, use, or recover
4. Envie intense Craving fort pour l'alcool
5. Effets indésirables Failure to fulfill obligations due to drinking
6. Problèmes interpersonnels Usage malgré des problèmes sociaux ou interpersonnels
7. Activités abandonnées Réduction d'activités importantes à cause de l'alcool
8. Situations dangereuses Usage dans des situations physiquement dangereuses
9. Problèmes de santé Utilisation malgré des problèmes physiques ou psychologiques
10. Tolérance Need for increased amount to achieve desired effect
11. Sevrage Caractéristiques de sevrage ou consommation pour éviter les symptômes
✅ Classification CIM-11 :
  • QE10 — Consommation dangereuse d'alcool
  • 6B10 — Trouble liés à l'usage d'alcool (syndrome de dépendance)
  • 6B11 — Trouble lié à l'usage d'alcool (usage nocif)
"La dépendance à l'alcool a été décrite pour la première fois comme un syndrome clinique par Edwards et Gross en 1976." — The Lancet 2025
🌍
Épidémiologie mondiale
Prévalence, distribution, facteurs de risque
▼
🌍 Statistiques mondiales :
Indicateur Valeur
Personnes avec troubles liés à l'usage d'alcool ~400 millions dans le monde
Décès annuels liés à l'alcool ~3 millions
Prévalence dans pays à revenu élevé Plus élevée
Prévalence dans pays à faible revenu Plus faible mais en augmentation
Patients réellement traités ~20% seulement
📊 Facteurs de risque pour les troubles liés à l'alcool :
Facteur Influence
Génétique Héritabilité estimée à 50-60%
Environnement familial Antécédents familiaux de troubles
Trauma psychologique TSPT, abuse dans l'enfance
Stress chronique Pression professionnelle, financière
Disponibilité de l'alcool Inversement lié aux prix et réglementations
Facteurs culturels Normes sociales concernant la consommation
⚠️ Impact du COVID-19 :
  • Augmentation de la mortalité entièrement attribuable à l'alcool
  • Interactions spécifiques entre alcool et stress pandémique
  • Émergence de consommations plus problématiques chez les personnes déjà vulnérables
  • Réduction de l'accès aux soins pour les troubles liés à l'alcool
💰
Coûts sociaux et économiques
Impact sur la société et le système de santé
▼
💰 Coûts sociaux de l'alcool :

Les coûts sociaux de la consommation d'alcool sont largement sous-financés par les taxes actuelles sur l'alcool.

Catégorie de coûts Estimation
Soins de santé Hospitalisations, urgences, traitement des maladies alcooliques
Perte de productivité Absentéisme, présentée, incapacité de travail
Accidents de la route Décès, blessures, coûts matériels
Criminalité Infractions liées à l'alcool, incarcération
Aide sociale Programmes de prévention, traitement, réadaptation
⚠️ Solutions proposées :
  • Augmentation des taxes d'accise sur l'alcool
  • Ces taxes sont actuellement largement insuffisantes pour couvrir les coûts sociaux
  • L'augmentation réduirait les dépenses de santé en diminuant les hospitalisations
  • Génération de recettes supplémentaires pour financer la prévention et le traitement
✅ Politiques recommandées :
  • Augmentation significative des taxes sur les boissons alcoolisées
  • Restriction de la publicité pour l'alcool
  • Réglementation de la disponibilité (horaires, âge minimum)
  • Programmes de prévention dans les écoles et lieux de travail
💊
Traitements validés scientifiquement
Interventions psychosociales, communautaires et pharmacologiques
▼
💊 Types de traitements disponibles :
Type Description Efficacité
Interventions psychosociales Brief interventions, motivational interviewing, CBT Élevée
Thérapies communautaires Groupes d'entraide, programmes résidentiels Élevée
Traitements pharmacologiques Naltrexone, disulfiram, baclofène, nalméfène Modérée à élevée
Détoxification Gestion du sevrage dans un cadre médical Necessaire
🔬 Médicaments approuvés pour le trouble lié à l'alcool :
Médicament Mécanisme Efficacité
Naltrexone Antagoniste des récepteurs opioïdes Réduit les envie et la consommation
Disulfiram Inhibiteur de l'aldéhyde déshydrogénase Effet dissuasif (réaction indésirables avec alcool)
Baclofène Agoniste GABA-B Réduction de la consommation (usage compassionnel)
Nalméfène Antagoniste opioïde Réduction de la consommation heavy
⚠️ Obstacles à l'accès aux traitements :
Obstacle Description
Faible disponibilité Absence de financement public pour les traitements
Stigmatisation Peur du jugement, honte, discrimination
Manque de formation Les professionnels de santé ne sont pas formés
Coûts Traitements non remboursés dans many pays
"Malgré leur forte prévalence, les troubles liés à l'usage d'alcool restent insuffisamment traités, même s'il existe des interventions scientifiquement validées et rentables." — Rehm et al., The Lancet 2025
🔬
Nouvelles modalités de traitement
Innovations et recherches en cours
▼
🔬 Innovations en cours de développement :
Modalité Description Statut
Thérapies digitales Applications de soutien, réalité virtuelle, chatbots En évaluation
Stimulation magnétique transcrânienne Traitement de la dépendance par neurostimulation Essais cliniques
Vaccins anti-alcool Réponse immune contre l'acétaldéhyde Recherche préliminaire
Médicaments de précision Traitement basé sur le profil génétique En développement
Thérapies géniques Modulation des gènes impliqués dans la dépendance Recherche fondamentale
🧠 Recherche sur les biomarqueurs :
  • Identification de marqueurs génétiques prédisant la réponse au traitement
  • Développement de tests pour identifier les patients à risque élevé
  • Recherche sur les marqueurs protéiques du craving
✅ Avancées prometteuses :
  • Les applications mobiles montrent des résultats préliminaires encourageants
  • La combinaison de traitements pharmacologiques et psychologiques est plus efficace
  • L'intelligence artificielle pourrait personnaliser les interventions
🏛️
Politiques de santé publique intégrées
Prévention, accès aux soins, réduction de la stigmatisation
▼
🏛️ Objectifs des politiques intégrées :
"Des politiques intégrées de contrôle de l'alcool pourraient améliorer la prévention des troubles liés à la consommation d'alcool, faciliter l'accès aux traitements et réduire la stigmatisation." — Rehm et al., The Lancet 2025
⚠️ Stratégies de contrôle de l'alcool (OMS) :
Stratégie Description Impact
Taxation Augmentation significative des taxes sur l'alcool Élevé
Restriction de la publicité Interdiction ou limitation de la publicité pour l'alcool Modéré
Réglementation de la disponibilité Contrôle des heures de vente, âge minimum Élevé
Étiquetage obligatoire Avertissements sanitaires sur les emballages Modéré
Programmes de prévention Éducation dans les écoles, lieux de travail Modéré à élevé
Accès aux soins Financement public des traitements Élevé
✅ Réduction de la stigmatisation :
  • Campagnes de sensibilisation du public
  • Formation des professionnels de santé
  • Intégration des soins pour troubles liés à l'alcool dans le système de santé général
  • Approche non-jugeante et centrée sur le patient
📚
Références bibliographiques
Articles scientifiques et liens cliquables
▼
📖 Article principal :
📚 Références bibliographiques complètes :
  • [1] Carvalho AF, Heilig M, Perez A, et al. Alcohol use disorders. Lancet. 2019; 394:781-792.
  • [2] American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). APA, Washington, DC, 2013.
  • [3] OMS. CIM-10 : descriptions cliniques et lignes directrices diagnostiques. OMS, Genève, 1992.
  • [4] OMS. CIM-11 pour les statistiques de mortalité et de morbidité : QE10 hazardous alcohol use. 2018.
  • [5] Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. BMJ. 1976; 1:1058-1061.
  • [6] American Psychiatric Association. Updates to DSM-5-TR criteria and text. Psychiatry.org, 2024.
  • [7] Degenhardt L, Bharat C, Bruno R, et al. Concordance between ICD-11 and other classification systems for alcohol and cannabis use disorders. Addiction. 2019; 114:534-552.
  • [8] Rehm J, Room R. Cultural specificity in alcohol use disorders. Lancet. 2022; 399:e7-e8.
  • [9] Rehm J, Room R. The cultural aspect: how to measure and interpret epidemiological data on alcohol-use disorders across cultures. Nord Alkohol-Narkotikatidskrift. 2017; 34:330-341.
  • [10] MacKillop J, Agabio R, Feldstein Ewing SW, et al. Hazardous drinking and alcohol use disorders. Nat Rev Dis Primers. 2022; 8:80.
  • [11] Rehm J, Heilig M, Gual A. ICD-11 for alcohol use disorders: not a convincing answer to the challenges. Alcohol Clin Exp Res. 2019; 43:2296-2300.
  • [12] Wakefield JC. Diagnostic issues and controversies in DSM-5: return of the false positives problem. Annu Rev Clin Psychol. 2016; 12:105-132.
  • [13] Rehm J, Anderson P, Barry J, et al. Prevalence and potential influencing factors for alcohol dependence in Europe. Eur Addict Res. 2015; 21:6-18.
  • [14] OMS. Global status report on alcohol and health and treatment of substance use disorders. OMS, 2024.
  • [15] OMS. Global Information System on Alcohol and Health (GISAH). who.int, 2025.
  • [16] Rehm J, Shield KD, Bunova A, et al. Prevalence of alcohol use disorders in primary health-care facilities in Russia in 2019. Addiction. 2022; 117:1640-1646.
  • [17] Kirzhanova VV, Grigorova NI, Bobkov EN, et al. State and activities of the narcological service of the Russian Federation in 2021. 2022.
  • [18] Mekonen T, Chan GCK, Connor J, et al. Treatment rates for alcohol use disorders: a systematic review and meta-analysis. Addiction. 2021; 116:2617-2634.
  • [19] UN Population Division. World population prospects 2019. UN, 2019.
  • [20] World Bank Group. World Bank Open Data: GDP per capita, PPP. data.worldbank.org, 2025.
  • [21] OMS. Global health estimates: leading causes of DALYs. OMS, 2025.
  • [22] Deak JD, Miller AP, Gizer IR. Genetics of alcohol use disorder: a review. Curr Opin Psychol. 2019; 27:56-61.
  • [23] Verhulst B, Neale MC, Kendler KS. Heritability of alcohol use disorders: a meta-analysis. Psychol Med. 2015; 45:1061-1072.
  • [24] Young-Wolff KC, Enoch MA, Prescott CA. The influence of gene-environment interactions on alcohol consumption and AUD. Clin Psychol Rev. 2011; 31:800-816.
  • [25] Agrawal A, Brislin SJ, Buchholz KK, et al. Collaborative Study on the Genetics of Alcoholism: overview. Genes Brain Behav. 2023; 22:e12864.
  • [26] Dick DM, Balcke E, McCutcheon V, et al. Collaborative Study on the Genetics of Alcoholism: sample and clinical data. Genes Brain Behav. 2023; 22:e12860.
  • [27] Gustavson DE, Bell TR, Buchholz EJ, et al. Genetic and environmental influences on alcohol consumption in middle to late life. Psychol Addict Behav. 2025. DOI: 10.1037/adb0001052
  • [28] European Medicines Agency. Guideline on development of medicinal products for treatment of alcohol dependence. EMA, 2010.
  • [29] Kilian C, Carr S, Schulte B, et al. Increased alcohol-specific mortality in Germany during COVID-19: state-level trends 2010-2020. Drug Alcohol Rev. 2023; 42:633-640.
  • [30] Kraus L, Möckl J, Manthey J, et al. Trends in alcohol-attributable morbidity and mortality in Germany 2000-2021. Drug Alcohol Rev. 2024; 43:1662-1675.
  • [31] Angus C, Buckley C, Tilstra AM, et al. Increases in deaths of despair during COVID-19 pandemic in US and UK. Santé Publique. 2023; 218:92-96.
  • [32] National Institute on Alcohol Abuse and Alcoholism. Alcohol-related deaths continued to rise in 2021. NIAAA, 2023.
  • [33] White AM, Castle IP, Powell PA, et al. Alcohol-related deaths during the COVID-19 pandemic. JAMA. 2022; 327:1704-1706.
  • [34] Yeo YH, He X, Ting PS, et al. Evaluation of trends in alcohol use disorder-related mortality in US before and during COVID-19. JAMA Netw Open. 2022; 5:e2210259.
  • [35] Rehm J, Tran A, Hassan AS, et al. Trends of fully alcohol-attributable mortality rates before and during COVID-19 in Baltic and other European countries. Scand J Public Health. 2025; 53:482-489.
  • [36] Rehm J, Gmel GE Sr, Gmel G, et al. The relationship between different dimensions of alcohol use and burden of disease: an update. Addiction. 2017; 112:968-1001.
  • [37] Schwarzinger M, Ferreira-Borges C, Neufeld M, et al. Alcohol rehabilitation and cancer risk: nationwide hospital cohort study in France. Lancet Public Health. 2024; 9:e461-e469.
  • [38] Rehm J. Covid-19, polarization of substance use, and mental health. J Pediatr. 2024; 100:340-342.
  • [39] Koob GF, Powell P, White A. Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19. Am J Psychiatry. 2020; 177:1031-1037.
  • [40] Wolkowicz NR, Peltier MR, Wemm S, et al. Subjective stress and alcohol consumption in young adults: systematic review of intensive longitudinal designs. Drug Alcohol Depend Rep. 2022; 3:100039.
  • [41] Yazdi K, Fuchs-Leitner I, Rosenleitner J, et al. Impact of the COVID-19 pandemic on patients with alcohol use disorder and associated risk factors for relapse. Front Psychiatry. 2020; 11:620612.
  • [42] Daigre C, Palma-Álvarez RF, Sorribes-Puertas M, et al. Abstinence duration and psychopathology among addiction outpatients during 18 months of COVID-19. Front Psychiatry. 2024; 15:1339730.
  • [43] Haun HL, Lebonville CL, Solomon MG, et al. Dynorphin/kappa opioid receptor activity within the extended amygdala contributes to stress-enhanced alcohol drinking in mice. Biol Psychiatry. 2022; 91:1019-1028.
  • [44] Sommer WH, Rimondini R, Hansson AC, et al. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala CRHR1 expression following a history of dependence. Biol Psychiatry. 2008; 63:139-145.
  • [45] Acuff SF, Strickland JC, Tucker JA, et al. Changes in alcohol use during COVID-19 and associations with contextual and individual difference variables: systematic review and meta-analysis. Psychol Addict Behav. 2022; 36:1-19.
  • [46] Kilian C, O'Donnell A, Potapova N, et al. Changes in alcohol use during the COVID-19 pandemic in Europe: a meta-analysis of observational studies. Drug Alcohol Rev. 2022; 41:918-931.
  • [47] Roberts A, Rogers J, Mason R, et al. Alcohol and other substance use during the COVID-19 pandemic: a systematic review. Drug Alcohol Depend. 2021; 229:109150.
  • [48] Sohi I, Chrystoja BR, Rehm J, et al. Changes in alcohol use during the COVID-19 pandemic and previous pandemics: systematic review. Alcohol Clin Exp Res. 2022; 46:498-513.
  • [49] Schmidt RA, Genois R, Jin J, et al. Early impact of COVID-19 on incidence, prevalence, and severity of alcohol and other drug use: systematic review. Drug Alcohol Depend. 2021; 228:109065.
  • [50] Rehm J, Patra J, Brennan A, et al. The role of alcohol use in the aetiology and progression of liver disease: narrative review and quantification. Drug Alcohol Rev. 2021; 40:1377-1386.
  • [51] Rehm J, Kilian C, Ferreira-Borges C, et al. Alcohol use in times of the COVID-19: implications for monitoring and policy. Drug Alcohol Rev. 2020; 39:301-304.
  • [52] de Goeij MC, Suhrcke M, Toffolutti V, et al. How economic crises affect alcohol consumption and alcohol-related health problems: realist systematic review. Soc Sci Med. 2015; 131:131-146.
  • [53] Schwarzinger M, Luchini S, Teschl M, et al. Mental disorders, COVID-19-related life-saving measures and mortality in France: nationwide cohort study. PLoS Med. 2023; 20:e1004134.
  • [54] Bruneau J, Rehm J, Wild TC, et al. Telemedicine support for addiction treatment services: National Rapid Guidance Document. Version 1. CRISM, 2020.
  • [55] López-Pelayo H, Aubin HJ, Drummond C, et al. The post-COVID era: challenges in the treatment of substance use disorder after the pandemic. BMC Med. 2020; 18:241.
  • [56] Lemp JM, Kilian C, Bright S, et al. Restrictive and permissive alcohol policies during COVID-19 and association with alcohol use in the United States. Int J Drug Policy. 2025; 140:104826.
  • [57] Rush B, Tremblay J, Babor TF. Needs-based planning for substance use treatment systems: the new generation of principles, methods, and models. J Stud Alcohol Drugs Suppl. 2019; S18:5-8.
  • [58] UN Statistics Division. SDG indicator metadata. UN, 2024.
  • [59] Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004; 82:858-866.
  • [60] Krupchanka D, Formanek T, Shield K, et al. International monitoring of capacity of treatment systems for alcohol and drug use disorders: methodology of the service capacity index. Int J Methods Psychiatr Res. 2023; 32:e1950.
  • [61] Han B, Jones CM, Einstein EB, et al. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021; 78:922-924.
  • [62] Donoghue K. Correlates and extent of prescribing of medications for alcohol relapse prevention in England. Addiction. 2021; 116:3019-3026.
  • [63] Morley KC, Logge W, Pearson SA, et al. National trends in alcohol pharmacotherapy: findings from an Australian claims database. Drug Alcohol Depend. 2016; 166:254-257.
  • [64] Wallhed Finn S, Lundin A, Sjöqvist H, et al. Pharmacotherapy for alcohol use disorders: unequal provision across sociodemographic factors and comorbidities. Drug Alcohol Depend. 2021; 227:108964.
  • [65] Wood E, Bright J, Hsu K, et al. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. CMAJ. 2023; 195:E1364-E1379.
  • [66] Kranzler HR, Vickers-Smith R. Addressing disparities in alcohol use disorder treatment: a call to action. Am J Psychiatry. 2024; 181:945-946.
  • [67] Le P, Rich JJ, Bernstein EY, et al. Disparities in treatment for alcohol use disorder among all of us participants. Am J Psychiatry. 2024; 181:973-987.
  • [68] Kilian C, Manthey J, Carr S, et al. Stigmatization of people with alcohol use disorders: updated systematic review. Alcohol Clin Exp Res. 2021; 45:899-911.
  • [69] Nemstov A. A contemporary history of alcohol in Russia. Södertörn University, 2011.
  • [70] Tomkins S, Saburova L, Kiryanov N, et al. Prevalence and socio-economic distribution of hazardous patterns of alcohol drinking in men aged 25-54 years in Izhevsk, Russia. Addiction. 2007; 102:544-553.
  • [71] Saburova L, Keenan K, Bobrova N, et al. Alcohol and fatal life trajectories in Russia: understanding accounts of premature male death in the family. BMC Public Health. 2011; 11:481.
  • [72] Leon DA, Saburova L, Tomkins S, et al. Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. Lancet. 2007; 369:2001-2009.
  • [73] Kirzhanova VV, Sidoryuk OV. Indicators of general and primary morbidity due to narcotic substance use disorders in Russian Federation 1999-2009. reabcentr.ru, 2010.
  • [74] Neufeld M, Bunova A, Gornyi B, et al. Russia's national concept to reduce alcohol abuse and alcohol-dependence 2010-2020: which policy targets have been achieved? Int J Environ Res Public Health. 2020; 17:8270.
  • [75] Government of the Russian Federation. Directive No. 3547-r: approval of the concept for reducing alcohol consumption in the Russian Federation up to 2030 and beyond. docs.cntd.ru, 2023.
  • [76] Neufeld M, Rehm J, Bunova A, et al. Validation of a screening test for alcohol use, Russian Federation. Bull World Health Organ. 2021; 99:496-505.
  • [77] Ministry of Health of the Russian Federation. Order No. 668n: on approval of procedure for providing medical care for mental disorders. normativ.kontur.ru, 2022.
  • [78] Assanangkornchai S, Vichitkunakorn P. Facts and figures: alcohol in Thailand 2019-2021. cas.or.th, 2022.
  • [79] Burden of Disease Thailand Study Group. Burden of disease attributable to risk factors in Thailand 2019. bodthai.net, 2023.
  • [80] Kittirattanapaiboon P, Tantirangsee N, Chutha W, et al. Prevalence of mental disorders and mental health problems: Thai national mental health survey 2013. J Ment Health Thail. 2017; 25:1-19.
  • [81] Assanangkornchai S, Nontarak J, Aekplakorn W, et al. Socio-economic inequalities in association between alcohol use disorder and depressive disorder among Thai adults. BMC Psychiatry. 2020; 20:553.
  • [82] Kumphang R, Chinkum D, Hatnontum P, et al. Study report on access to care services for people with alcohol-related problems. HITAP, Nonthaburi, 2021.
  • [83] Kittirattanapaiboon P. Guidelines for screening, treatment and rehabilitation for people with alcohol use disorders. National Alcohol Control Committee, Nonthaburi, 2018.
  • [84] Likhitsathian S, Uttawichai K, Booncharoen H, et al. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: 12-week randomized placebo-controlled trial. Drug Alcohol Depend. 2013; 133:440-446.
  • [85] Sethabouppha H, Ratsameesuwiwa J, Oopkam N, et al. Effects of the KlaiBann Samanjai Program on drinking behaviors, quality of life, and readmission among persons with alcohol dependence in southern Thailand. Nurs J. 2015; 42:107-119.
  • [86] Tanaree A, Assanangkornchai S, Isaranuwatchai W, et al. Integrated treatment program for alcohol-related problems in community hospitals Songkhla province, Thailand: social return on investment analysis. PLoS One. 2019; 14:e0209210.
  • [87] Koob GF. Alcohol use disorder treatment: problems and solutions. Annu Rev Pharmacol Toxicol. 2024; 64:255-275.
  • [88] Ghosh A, Morgan N, Calvey T, et al. Effectiveness of psychosocial interventions for alcohol use disorder: systematic review and meta-analysis update. Am J Drug Alcohol Abuse. 2024; 50:442-454.
  • [89] McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: systematic review and meta-analysis. JAMA. 2023; 330:1653-1665.
  • [90] Smedslund G, Berg RC, Hammerstrøm KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011; CD008063.
  • [91] Magill M, Ray L, Kiluk B, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J Consult Clin Psychol. 2019; 87:1093-1105.
  • [92] Ray LA, Meredith LR, Kiluk BD, et al. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: systematic review and meta-analysis. JAMA Netw Open. 2020; 3:e208279.
  • [93] Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol. 2006; 26(suppl 1):S37-S42.
  • [94] Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020; 3:CD012880.
  • [95] Magill M, Kiluk BD, McCrady BS, et al. Active ingredients of treatment and client mechanisms of change in behavioral treatments for AUD: progress 10 years later. Alcohol Clin Exp Res. 2015; 39:1852-1862.
  • [96] International Agency for Research on Cancer. Alcohol policies. IARC handbooks of cancer prevention, volume 20B. IARC, 2025.
  • [97] Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016; 387:988-998.
  • [98] Schuckit MA. Alcohol-use disorders. Lancet. 2009; 373:492-501.
  • [99] Kranzler HR. Overview of alcohol use disorder. Am J Psychiatry. 2023; 180:565-572.
  • [100] Reus VI, Fochtmann LJ, Bukstein O, et al. APA practice guideline for pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018; 175:86-90.
  • [101] Soyka M, Kranzler HR, Hesselbrock V, et al. Guidelines for biological treatment of substance use disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017; 18:86-119.
  • [102] National Institute for Health and Care Excellence. Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. NICE, 2014.
  • [103] Soyka M, Rösner S. Modern pharmacotherapy guidance for treating alcohol use disorders. Expert Opin Pharmacother. 2025; 26:147-156.
  • [104] Kulig CC, Beresford TP. Hepatitis C in alcohol dependence: drinking versus disulfiram. J Addict Dis. 2005; 24:77-89.
  • [105] Yahn SL, Watterson LR, Olive MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse. 2013; 6:1-12.
  • [106] WHO. WHO model list of essential medicines—23rd list, 2023. who.int, 2023.
  • [107] Leucht S, Helfer B, Gartlehner G, et al. How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Med. 2015; 13:253.
  • [108] Mendes FR, dos Santos Costa C, Wiltenburg VD, et al. Classic and non-classic psychedelics for substance use disorder: historic, past and current research. Addict Neurosci. 2022; 3:100025.
  • [109] Jerlhag E. The therapeutic potential of GLP-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023; 14:1063033.
  • [110] Subhani M, Dhanda A, King JA, et al. Association between GLP-1 receptor agonists use and change in alcohol consumption: systematic review. EClinicalMedicine. 2024; 78:102920.
  • [111] Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: randomized clinical trial. JAMA Psychiatry. 2025; 82:395-405.
  • [112] Leggio L, Hendershot CS, Farokhnia M, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023; 29:2993-2995.
  • [113] Bruns Vi N, Tressler EH, Vendruscolo LF, et al. IUPHAR review: GLP-1 and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol Res. 2024; 207:107312.
  • [114] Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024; 15:4548.
  • [115] Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022; 7:e159863.
  • [116] Probst L, Monnerat S, Vogt DR, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023; 8:e170419.
  • [117] Shi I, Khan SS, Yeh RW, et al. Semaglutide eligibility across all current indications for US adults. JAMA Cardiol. 2024; 10:96-98.
  • [118] Volkow ND, Xu R. GLP-1R agonist medications for addiction treatment. Addiction. 2024; 120:198-200.
  • [119] Fang L, Li J, Zeng H, et al. Effects of GLP-1 receptor agonists on liver fibrosis and CRP in NAFLD/NASH: systematic review and meta-analysis. Prim Care Diabetes. 2024; 18:268-276.
  • [120] Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel. J Hepatol. 2025; 82:744-756.
  • [121] Balakrishnan M, Rehm J. A public health perspective on mitigating the global burden of chronic liver disease. Hepatology. 2024; 79:451-459.
  • [122] Dellgren JL, Persad G, Emanuel EJ. International coverage of GLP-1 receptor agonists: review and ethical analysis. Lancet. 2024; 404:902-906.
  • [123] Rodriguez LA, Finertie H, Neugebauer RS, et al. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Lancet Reg Health Am. 2024; 34:100759.
  • [124] Day E, Pechey LC, Roscoe S, et al. Recovery support services as part of the continuum of care for alcohol or drug use disorders. Addiction. 2025; 120:1497-1520.
  • [125] Kelly J. Report of findings from a systematic review of the scientific literature on recovery support services in the United States. mass.gov, 2017.
  • [126] Kelly JF, Bergman B, Hoeppner BB, et al. Prevalence and pathways of recovery from drug and alcohol problems in the United States population. Drug Alcohol Depend. 2017; 181:162-169.
  • [127] Samokhvalov AV, Popova S, Room R, et al. Disability associated with alcohol abuse and dependence. Alcohol Clin Exp Res. 2010; 34:1871-1878.
  • [128] Roerecke M, Rehm J. Alcohol use disorders and mortality: a systematic review and meta-analysis. Addiction. 2013; 108:1562-1578.
  • [129] Charlson FJ, Baxter AJ, Dua T, et al. Excess mortality from mental, neurological, and substance use disorders in the global burden of disease study 2010. In: Patel V, Dua T, Laxminarayan R, editors. Mental, neurological, and substance use disorders, disease control priorities. World Bank; 2016. p. 41-65.
  • [130] Rehm J, Shield KD, Gmel G, et al. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013; 23:89-97.
  • [131] UN. Tobacco and other health taxes for healthier population. Action area a: domestic public resources. UN, 2024.
  • [132] Neufeld M, Rovira P, Ferreira-Borges C, et al. Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European Region: a modelling study. Lancet Reg Health Eur. 2022; 15:100325.
  • [133] WHO. Global report on the use of alcohol taxes, 2023. who.int, 2023.
  • [134] Manthey J, Hassan SA, Carr S, et al. What are the economic costs to society attributable to alcohol use? A systematic review and modelling study. PharmacoEconomics. 2021; 39:809-822.
  • [135] WHO. Raise taxes on tobacco. who.int, 2025.
  • [136] World Health Organization. Universal health coverage. who.int, 2025.
  • [137] Alayed TM, Alrumeh AS, Alkanhal IA, et al. Impact of privatization on healthcare system: a systematic review. Saudi J Med Med Sci. 2024; 12:125-133.
  • [138] Goodair B, Reeves A. The effect of health-care privatisation on the quality of care. Lancet Public Health. 2024; 9:e199-e206.
  • [139] Rehm J, Rovira P, Hassan AS, et al. A return on investment analysis for the 2017 increase in alcohol excise taxation in Lithuania. Addiction. 2025; 120:2094-2104.
  • [140] Babor TF, Casswell S, Graham K, et al. Alcohol: no ordinary commodity—research and public policy. 3rd ed. Oxford University Press; 2023.
  • [141] Rehm J, Badaras R, Ferreira-Borges C, et al. Impact of the WHO "best buys" for alcohol policy on consumption and health in the Baltic countries and Poland 2000-2020. Lancet Reg Health Eur. 2023; 33:100704.
  • [142] WHO. WHO technical manual on alcohol tax policy and administration. who.int, 2023.
  • [143] Kaiser K-A, Bredenkamp C, Iglesias RM. Sin tax reform in the Philippines: transforming public finance, health, and governance for more inclusive development. World Bank, 2016.
🔗 Liens utiles :